-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on NeoGenomics, Lowers Price Target to $8.5

Benzinga·04/29/2025 17:43:21
Listen to the news
Needham analyst Mike Matson maintains NeoGenomics (NASDAQ:NEO) with a Buy and lowers the price target from $18 to $8.5.